The Monday biotech signal
Trial evidence sharpens. Monday hiring accelerates.
Enhertu improves progression-free survival while 131 active biopharma opportunities added before cutoff are 89.9% above last Monday.
JobReports original editorial image
131
Active biopharma jobs added
20
Biopharma employers
+89.9%
Versus last Monday
40
Commercial & business roles
This dated issue is part of the public report archive. See the service update for account availability.
Oncology / Phase III
Enhertu delays progression in first-line HER2-mutant lung cancer, while survival remains unsettled
AstraZeneca and Daiichi Sankyo said the 454-patient DESTINY-Lung04 trial improved median progression-free survival to 14.3 months with Enhertu, compared with 8.3 months for pembrolizumab plus chemotherapy. The blinded-review hazard ratio was 0.63, and response rates were 70.0% versus 44.5%.
The overall-survival analysis was only 46.9% mature, with no formal hypothesis test and no observed survival benefit at this cut. Adjudicated interstitial lung disease or pneumonitis occurred in 20.8% of Enhertu-treated patients, including four fatal events. Those limits matter alongside the progression result.
Why it matters
A positive primary endpoint can shift work toward regulatory review and biomarker-enabled launch planning, while the immature survival analysis and ILD profile keep drug-safety, medical, and evidence-generation functions central. The companies did not announce hiring tied to the readout.
Immuno-oncology / Updated survival
Gotistobart posts an 18.5-month median survival in a non-pivotal Phase 3 stage
BioNTech and OncoC4 reported median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in the 87-patient stage 1 of PRESERVE-003 (HR 0.56; nominal p=0.0295). Grade 3 or higher treatment-related adverse events occurred in 44.4% and 48.8% of patients, respectively.
Stage 1 was the non-pivotal portion. The separate pivotal stage 2 remains underway at more than 160 sites, so this update is not the confirmatory readout.
Infectious disease / FDA designation
Armata's AP-SA02 wins Breakthrough Therapy designation ahead of planned Phase 3
FDA granted Breakthrough Therapy designation to Armata's investigational intravenous phage cocktail for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.
Armata linked the designation to Phase 1b/2a evidence and plans a Phase 3 superiority study in the second half of 2026. A development designation can speed FDA interaction; it is not an approval or proof of Phase 3 success.
Monday volume nearly doubles from last week
JobReports added 131 active biotechnology and pharmaceutical opportunities from 20 employers between midnight Eastern and today's cutoff. That is 89.9% above the 69 opportunities in the comparable Monday window one week earlier. Commercial and business was the largest named role family, followed by manufacturing and operations and clinical and medical work.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional. The hiring sample is independent of today's news announcements and does not imply those companies created these jobs.
7
Los Angeles roles
5
Indianapolis roles
3
North Kingstown roles
2
Austin roles
2
New Brunswick roles
Editor's shortlist
Five roles worth a closer look
Manager, Clinical Pharmacology
San Diego, California · Onsite
Global Development Medical Director, Hematology Oncology
Cambridge / Boston, Massachusetts
Supervisor, Quality Control
Indianapolis, Indiana · Onsite
Associate Principal Scientist, Downstream Process Development
Rahway, New Jersey
Oncology Sales Representative – Head & Neck, New England
Boston / Springfield, MA · Manchester, NH
The takeaway
The evidence is consequential—and the unresolved work is visible.
Enhertu's progression result arrives with an immature survival analysis and a safety burden that demand careful follow-through. Gotistobart's updated result still awaits its pivotal test, and AP-SA02's FDA designation precedes Phase 3. Today's verified openings offer a separate path into clinical development, pharmacology, quality, process science, and oncology commercialization.